MBX Biosciences (MBX) Competitors $10.23 +0.34 (+3.44%) Closing price 04:00 PM EasternExtended Trading$9.75 -0.48 (-4.69%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends MBX vs. GLPG, ARQT, INDV, AKRO, DYN, IMCR, EVO, TVTX, VIR, and GPCRShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Immunocore (IMCR), Evotec (EVO), Travere Therapeutics (TVTX), Vir Biotechnology (VIR), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Galapagos Arcutis Biotherapeutics Indivior Akero Therapeutics Dyne Therapeutics Immunocore Evotec Travere Therapeutics Vir Biotechnology Structure Therapeutics Galapagos (NASDAQ:GLPG) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Does the media refer more to GLPG or MBX? In the previous week, Galapagos' average media sentiment score of 0.12 beat MBX Biosciences' score of 0.00 indicating that Galapagos is being referred to more favorably in the media. Company Overall Sentiment Galapagos Neutral MBX Biosciences Neutral Do analysts prefer GLPG or MBX? Galapagos presently has a consensus target price of $30.75, indicating a potential upside of 30.35%. MBX Biosciences has a consensus target price of $37.25, indicating a potential upside of 286.81%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe MBX Biosciences is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galapagos 3 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.63MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GLPG or MBX more profitable? Company Net Margins Return on Equity Return on Assets GalapagosN/A N/A N/A MBX Biosciences N/A N/A N/A Do insiders & institutionals believe in GLPG or MBX? 32.5% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, GLPG or MBX? Galapagos has higher revenue and earnings than MBX Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalapagos$259.40M5.99$229.12MN/AN/AMBX BiosciencesN/AN/AN/AN/AN/A Does the MarketBeat Community believe in GLPG or MBX? Galapagos received 462 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 64.01% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformGalapagosOutperform Votes46664.01% Underperform Votes26235.99% MBX BiosciencesOutperform Votes4100.00% Underperform VotesNo Votes SummaryGalapagos beats MBX Biosciences on 5 of the 9 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$321.84M$6.55B$5.37B$19.99BDividend YieldN/A2.96%5.37%3.61%P/E RatioN/A9.4686.7641.58Price / SalesN/A318.651,278.6017.38Price / CashN/A22.6336.6017.54Price / BookN/A5.034.925.82Net IncomeN/A$154.90M$117.96M$1.01B7 Day Performance-20.02%2.08%2.19%2.97%1 Month Performance-52.70%1.07%3.21%5.47%1 Year PerformanceN/A4.19%26.71%19.77% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX BiosciencesN/A$10.23+3.4%$37.25+264.1%N/A$341.86MN/A0.0036GLPGGalapagos1.3995 of 5 stars$24.24-5.5%$30.75+26.9%-36.9%$1.60B$260.09M0.001,123ARQTArcutis Biotherapeutics2.174 of 5 stars$13.63-1.3%$16.60+21.8%+290.2%$1.60B$138.71M-7.61150INDVIndivior2.4636 of 5 stars$11.51-2.9%$16.00+39.0%-26.9%$1.59B$1.18B-287.681,164Short Interest ↑News CoveragePositive NewsGap UpAKROAkero Therapeutics3.9442 of 5 stars$22.63-8.9%$46.83+107.0%+14.7%$1.58BN/A-6.0330DYNDyne Therapeutics3.6048 of 5 stars$15.29-3.7%$49.91+226.4%-9.5%$1.56BN/A-4.29100News CoverageIMCRImmunocore2.4857 of 5 stars$30.03-1.2%$65.64+118.6%-58.6%$1.50B$296.31M-31.61497EVOEvotec2.0123 of 5 stars$4.18-4.1%$5.93+41.9%-47.5%$1.48B$777.05M0.004,200Positive NewsTVTXTravere Therapeutics2.1328 of 5 stars$18.59+2.8%$23.67+27.3%+110.2%$1.45B$203.45M-4.09460Analyst RevisionVIRVir Biotechnology4.2194 of 5 stars$10.52-13.1%$34.83+231.1%+6.5%$1.45B$62.04M-2.68580Positive NewsGPCRStructure Therapeutics1.5829 of 5 stars$25.16-0.4%$81.29+223.1%-33.6%$1.44BN/A-34.00136Short Interest ↑ Related Companies and Tools Related Companies Galapagos Competitors Arcutis Biotherapeutics Competitors Indivior Competitors Akero Therapeutics Competitors Dyne Therapeutics Competitors Immunocore Competitors Evotec Competitors Travere Therapeutics Competitors Vir Biotechnology Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:MBX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
